Affle shares rally as Q2 growth reinforces Perion deal
after close1 source ↓machine-written, see hownot a recommendation
- AFFLE close
- ₹1,342
- On the day
- -2.86%
- 52-week high
- ₹1,960
- 52-week low
- ₹1,251
Affle 3i shares traded over 10% higher on 02 Nov 2026 after the company reported stronger Q2 FY27 operating performance, with revenue, EBITDA and margins improving both year-on-year and sequentially. CNBC TV18 reported the move alongside the company’s planned US$420 million acquisition of Perion, which was announced on 01 Nov 2026. 📈
Consolidated revenue from operations rose 21% year-on-year to ₹783 crore in the September quarter, compared with ₹647 crore a year earlier. Revenue also increased 5.5% quarter-on-quarter from ₹742 crore in Q1 FY27. EBITDA ₹181 cr grew 24% year-on-year from ₹146.40 crore and 13% sequentially from ₹160.47 crore.
The EBITDA margin 23.12% improved from 22.63% in Q2 FY26 and 21.63% in Q1 FY27. Profit after tax rose 18% year-on-year, although the excerpt did not provide the corresponding reported amount. The improvement in profitability gives the digital advertising business a stronger operating backdrop as investors assess the funding and integration implications of the Perion transaction. 💻
The acquisition remains subject to regulatory clearances and Perion shareholder approval, with closing expected in early 2027. Affle’s Israel-based step-down subsidiary plans to fund the all-cash transaction through committed bank financing from Citibank and available cash resources. Perion had approximately US$228 million in cash and no financial debt as of 30 Sep 2026.
OI Charts data showed Affle closing at ₹1,342 on 30 Oct 2026, down 2.9% on the day, with volume of 108,872 shares. The stock had declined 3.8% over five sessions and 13.3% over 20 sessions, with a 52-week range of ₹1,251 to ₹1,960. The reported rally therefore followed a recent period of weakness rather than an established short-term uptrend.
Investors will next watch the complete Q2 financial disclosures, management commentary on margins and the Perion acquisition, financing costs, regulatory approvals and the early-2027 closing timetable.
Source: CNBC TV18, 02 Nov 2026
Not investment advice. For informational purposes only.